Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-03-29 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
第三届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 17th meeting of the 3rd Board of Directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to other announcements published on the Beijing Stock Exchange website. The content focuses on board meeting decisions, such as approval of annual reports, financial budgets, appointment of auditors, capital changes, and governance matters. It does not contain the full annual report or financial statements but rather the board's resolutions and approvals related to these reports and other corporate governance matters. This type of document fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length (7873 characters) and detailed meeting minutes support this classification rather than a full Annual Report or other report types.
2023-03-29 Chinese
拟续聘会计师事务所公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's intention to renew the appointment of an accounting firm (auditor) for the 2023 fiscal year. It details the auditor's background, qualifications, past audit engagements, audit fees, and the approval process by the board and audit committee. There is no actual audit report or financial statements included, nor substantive financial data or analysis. The document is relatively short (4260 characters) and serves as a formal announcement of the auditor appointment process rather than the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-29 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司回购注销2021年限制性股票激励计划部分限制性股票相关事项之核查意见
Regulatory Filings
2023-03-29 Chinese
2022年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Plan Announcement" for the year 2022 by Jiangsu Deyuan Pharmaceutical Co., Ltd. It discusses the company's profit distribution plan, including cash dividends and stock dividends, based on the audited 2022 annual report. The document includes details on the board of directors' approval, independent directors' opinions, supervisory board opinions, and references to company bylaws and dividend policies. It is an announcement of a dividend distribution plan rather than the full annual report or financial statements. The document length is 3757 characters, which is relatively short and focused on the dividend plan announcement. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2023-03-29 Chinese
2022年年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (330 characters) indicating that the company's 2022 Annual Report and its summary have been disclosed on the official stock exchange information platform. It explicitly states that the report is available for investors to review and does not contain the report itself. This fits the pattern of a Report Publication Announcement (RPA) rather than the full Annual Report (10-K).
2023-03-29 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2022' which translates to 'Annual Report 2022'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal control, and financial accounting reports. It includes audited financial data, auditor's opinion (standard unqualified opinion), and detailed financial statements. The document length is substantial (15,000 characters) and contains comprehensive financial and operational information for the fiscal year 2022. Therefore, this document is the official yearly report covering company activity and full financial performance, fitting the definition of an Annual Report (10-K). FY 2022
2023-03-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.